Article

New solution available

A new multipurpose disinfecting solution (Opti-Free PureMoist, Alcon) is now available for contact lens wearers in the United States.

Huenenberg, Switzerland-A new multipurpose disinfecting solution (Opti-Free PureMoist, Alcon) is now available for contact lens wearers in the United States.

The solution contains a proprietary wetting agent (HydraGlyde Moisture Matrix) that, according to the manufacturer, has demonstrated the ability to provide 16 hours of lens wettability. The wetting agent, a synthetic block copolymer, is designed to embed itself on and within the lens surface to remove protein deposits and reduce lipid deposition, which has been shown to be an issue with certain silicone hydrogel lenses. The agent has an extremely high affinity for the hydrophobic areas of all soft contact lenses that are not wetted by the tear film, according to the manufacturer.

“Silicone hydrogel lenses have undergone tremendous advances in the past 10 years, and [the solution] was designed to address the need for progressive technologies to help improve the performance of these lenses,” said Howard Ketelson, PhD, director of vision care product research at Alcon. “In clinical trials, [the solution with its wetting agent] provided comfort and moisture from contact lens insertion to removal for both symptomatic and asymptomatic patients.”

The solution’s dual disinfectant system (Polyquad and Aldox), with a chelating agent, edetate disodium, is designed to provide antimicrobial efficacy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.